1-butyl-4-(2-methoxyphenyl)piperazine | 93151-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-butyl-4-(2-methoxyphenyl)piperazine
• 英文别名: 1-Butyl-4-(2-methoxy-phenyl)-piperazine
• CAS: 93151-61-2
• 化学式: C₁₅H₂₄N₂O
• 分子量: 248.368
• InChiKey: DCFYVNHQUVKFKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  15.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  正溴丁烷 、 1-(2-甲氧苯基)哌嗪 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 24.0h， 以36%的产率得到1-butyl-4-(2-methoxyphenyl)piperazine
  参考文献：
  名称：

  中枢神经系统制剂的结构活性关系研究。13.一种新型的5-HT1A受体拮抗剂4- [3-（苯并三唑-1-基）丙基] -1-（2-甲氧基苯基）哌嗪及其类似物。

  摘要：

  合成了一组新的含有末端苯并三唑片段的4-烷基-1-（邻甲氧基苯基）哌嗪，并确定了它们的5-HT1A和5-HT2亲和力。结果表明，苯并三唑部分有助于5-HT1A和5-HT2受体的亲和力。在几种行为模型中证明了4- [3-（苯并三唑-1-基）丙基] -1-（2-甲氧基苯基）哌嗪（11）是一种新型的有效的突触前和突触后5-HT1A受体拮抗剂。但是，它对5-HT1A相对于α1受体没有选择性。

  DOI：

  10.1021/jm00043a014

文献信息

• 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS
  申请人：Berardi Francesco

  公开号：US20090093493A1

  公开（公告）日：2009-04-09

  The invention relates to a new class of compounds, which are 1-phenylalcoxy-2-β-phenylethyl derivatives, as P-glycoprotein (P-GP) inhibitors. These compounds are useful in drug resistance events. They have been shown able to inhibit in a dose-dependent manner Glycoprotein-P (P-gp) activity in cell lines in which the expression of said glycoprotein is very high, like Caco-2 (human colon cancer) cells and MCF7/Adr (adriamycin-resistant human breast carcinoma) cells. The invention also relates to methods of production and the utilization of such compounds as medicaments useful in the treatment of states linked to the difficulty for some drugs to cross the blood-brain barrier (BBB) and generally within the context of the problems of drug resistance induced by chemotherapy agents.

  该发明涉及一类新化合物，即1-苯基羟基-2-β-苯乙基衍生物，作为P-糖蛋白（P-GP）抑制剂。这些化合物在药物耐药事件中很有用。已经证明它们能够以剂量依赖的方式抑制细胞系中的糖蛋白-P（P-gp）活性，其中所述糖蛋白的表达非常高，如Caco-2（人类结肠癌）细胞和MCF7/Adr（阿霉素耐药的人类乳腺癌）细胞。该发明还涉及生产方法和利用这类化合物作为药物的方法，用于治疗与某些药物跨越血脑屏障（BBB）困难相关的状态，以及在化疗药物引起的药物耐药问题背景下的一般情况。
• Structure-Activity Relationship Studies of Central Nervous System Agents. 13.4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a New Putative 5-HT1A Receptor Antagonist, and Its Analogs
  作者：Jerzy L. Mokrosz、Maria H. Paluchowska、Ewa Chojnacka-Wojcik、Malgorzata Filip、Sijka Charakchieva-Minol、Anna Deren-Wesolek、Maria J. Mokrosz

  DOI：10.1021/jm00043a014

  日期：1994.8

  and their 5-HT1A and 5-HT2 affinity was determined. It was shown that the benzotriazole moiety contributes to both the 5-HT1A and 5-HT2 receptor affinity. It was demonstrated in several behavioral models that 4-[3-(benzotriazol-1- yl)propyl]-1-(2-methoxyphenyl)piperazine (11) is a new, potent presynaptic and postsynaptic 5-HT1A receptor antagonist. However, it is not selective for 5-HT1A versus alpha

  合成了一组新的含有末端苯并三唑片段的4-烷基-1-（邻甲氧基苯基）哌嗪，并确定了它们的5-HT1A和5-HT2亲和力。结果表明，苯并三唑部分有助于5-HT1A和5-HT2受体的亲和力。在几种行为模型中证明了4- [3-（苯并三唑-1-基）丙基] -1-（2-甲氧基苯基）哌嗪（11）是一种新型的有效的突触前和突触后5-HT1A受体拮抗剂。但是，它对5-HT1A相对于α1受体没有选择性。
• N-PHENYLPIPERAZINE DERIVATIVES THAT ARE ANTAGONISTS OF A1A, A1D ADRENOCEPTORS AND 5-HT1A RECEPTORS FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：Universidade Federal Do Rio De Janeiro - UFRJ

  公开号：EP2810938A1

  公开（公告）日：2014-12-10

  The present invention provides N-phenylpiperazine derivatives for use as multiple binders and/or antagonists of α1A adrenoceptors, α1D adrenoceptors and 5-HT1A serotonin receptors. These substances are candidates to prototypes for the treatment of benign prostate hyperplasia and lower urinary tract symptoms, and are useful in pharmaceutical compositions.

  本发明提供了可用作α1A肾上腺素受体、α1D肾上腺素受体和5-HT1A血清素受体的多重结合剂和/或拮抗剂的N-苯基哌嗪衍生物。这些物质是治疗良性前列腺增生和下尿路症状的候选原型，可用于药物组合物中。
• Mokrosz Jerzy L., Paluchowska Maria H., Chojnacka-Wojcik Ewa, Filip Malgo+, J. Med. Chem, 37 (1994) N 17, S 2754-2760
  作者：Mokrosz Jerzy L., Paluchowska Maria H., Chojnacka-Wojcik Ewa, Filip Malgo+

  DOI：——

  日期：——
• US4755512A
  申请人：——

  公开号：US4755512A

  公开（公告）日：1988-07-05